Interaction of environmental factors and physical exercise in the development of amyotrophic lateral sclerosis and the potential of pharmacology and targeted therapies - a Narrative Review
DOI:
https://doi.org/10.12775/QS.2026.56.72469Keywords
ALS, ALS treatment, ALS risk factors, pesticides and ALS, Physical activity and ALSAbstract
Background: Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease leading to motor neuron degeneration and muscle atrophy. Its etiology remains unclear, although environmental and lifestyle factors may contribute to disease development.
Aim: This review analyzed the influence of environmental factors and physical activity on ALS risk, as well as current and emerging treatment strategies.
Material and methods: Articles published between 2017 and 2026 were reviewed using PubMed, GeneReviews, StatPearls, and Google Scholar databases. Original studies and review papers concerning ALS risk factors and therapies were included.
Results: Exposure to chlorinated pesticides, cadmium, lead, tobacco smoke, and cigarette smoking was associated with increased ALS risk. Studies on air pollution produced inconclusive findings. A higher ALS incidence was observed among NFL players, although the direct role of physical activity remains uncertain. Some large population studies suggested that regular physical activity may lower ALS risk. Despite available disease-modifying therapies, ALS remains incurable.
Conclusions: Exposure to pesticides and toxic metals may increase ALS risk and should be minimized. Evidence regarding physical activity and ALS is inconsistent and requires further research. Continued development
of therapies targeting ALS pathogenesis is necessary.
References
1. Brotman, R. G., Moreno-Escobar, M. C., Joseph, J., Munakomi, S., & Pawar, G. (2024). Amyotrophic Lateral Sclerosis. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: http://www.ncbi.nlm.nih.gov/books/NBK556151/
2. Araki, T. (Ed.). (2021). Amyotrophic Lateral Sclerosis. Brisbane (AU): Exon Publications. Available from: http://www.ncbi.nlm.nih.gov/books/NBK573426/
3. Julian, T. H., Glascow, N., Barry, A. D. F., Moll, T., Harvey, C., Klimentidis, Y. C., et al. (2021). Physical exercise is a risk factor for amyotrophic lateral sclerosis: Convergent evidence from Mendelian randomisation, transcriptomics and risk genotypes. EBioMedicine, 68, 103397. https://doi.org/10.1016/j.ebiom.2021.103397
4. Meyer, T. (2021). Amyotrophic lateral sclerosis (ALS) - diagnosis, course of disease and treatment options. Deutsche Medizinische Wochenschrift, 146(24-25), 1613-1618. https://doi.org/10.1055/a-1513-1815
5. Goutman, S. A., Hardiman, O., Al-Chalabi, A., Chió, A., Savelieff, M. G., Kiernan, M. C., et al. (2022). Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurology, 21(5), 480-493. https://doi.org/10.1016/S1474-4422(21)00465-8
6. Ryan, M., Heverin, M., McLaughlin, R. L., & Hardiman, O. (2019). Lifetime Risk and Heritability
of Amyotrophic Lateral Sclerosis. JAMA Neurology, 76(11), 1367-1374. https://doi.org/10.1001/jamaneurol.2019.2044
7. Masrori, P., & Van Damme, P. (2020). Amyotrophic lateral sclerosis: a clinical review. European Journal of Neurology, 27(10), 1918-1929. https://doi.org/10.1111/ene.14393
8. Engelberg-Cook, E., Shah, J. S., Teixeira da Silva Hucke, A., Vera-Garcia, D. V., Dagher, J. E., Donahue, M. H., et al. (2024). Prognostic Factors and Epidemiology of Amyotrophic Lateral Sclerosis in Southeastern United States. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 8(5), 482-492. https://doi.org/10.1016/j.mayocpiqo.2024.06.004
9. Pamphlett, R., & Parkin Kullmann, J. (2024). Early life events may be the first steps on the multistep path to amyotrophic lateral sclerosis. Scientific Reports, 14(1), 28497. https://doi.org/10.1038/s41598-024-79576-1
10. Siddique, N., & Siddique, T. (2026). Amyotrophic Lateral Sclerosis Overview. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1450/
11. Budrewicz, S., Słotwiński, K., Madetko, N., & Koszewicz, M. Zaburzenia połykania w chorobach układu nerwowego - diagnostyka i leczenie.
12. Ramroop, H., & Cruz, R. (2026). Electrodiagnostic Evaluation of Motor Neuron Disease. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: http://www.ncbi.nlm.nih.gov/books/NBK563178/
13. Arnulf, I., Similowski, T., Salachas, F., Garma, L., Mehiri, S., Attali, V., et al. (2000). Sleep disorders and diaphragmatic function in patients with amyotrophic lateral sclerosis. American Journal of Respiratory and Critical Care Medicine, 161(3 Pt 1), 849-856. https://doi.org/10.1164/ajrccm.161.3.9905047
14. Nijs, M., & Van Damme, P. (2024). The genetics of amyotrophic lateral sclerosis. Current Opinion in Neurology, 37(5), 560-569. https://doi.org/10.1097/WCO.0000000000001304
15. Beckers, J., Thakeshwar, A. K., & Van Damme, P. (2021). C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy, 17(11), 3306-3322. https://doi.org/10.1080/15548627.2021.1872229
16. Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314(5796), 130-133. https://doi.org/10.1126/science.1134108
17. Opie-Martin, S., Iacoangeli, A., Topp, S. D., Abel, O., Mayl, K., Mehta, P. R., et al. (2022). The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration. Nature Communications, 13(1), 6901. https://doi.org/10.1038/s41467-022-34595-2
18. Manohar, V., Crowley, L., & Sreedharan, J. TARDBP-Related Amyotrophic Lateral Sclerosis-Frontotemporal Dementia. In Adam, M. P., Bick, S., Mirzaa, G. M., et al. (Eds.), GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle. Available from: http://www.ncbi.nlm.nih.gov/books/NBK5942/
19. Parvanovova, P., Evinova, A., Grofik, M., Hnilicova, P., Tatarkova, Z., & Turcanova-Koprusakova, M. (2024). Mitochondrial Dysfunction in Sporadic Amyotrophic Lateral Sclerosis Patients: Insights from High-Resolution Respirometry. Biomedicines, 12(6), 1294. https://doi.org/10.3390/biomedicines12061294
20. Yin, X., Wang, S., Qi, Y., Wang, X., Jiang, H., Wang, T., et al. (2018). Astrocyte elevated gene-1 is a novel regulator of astrogliosis and excitatory amino acid transporter-2 via interplaying with nuclear factor-κB signaling in astrocytes from amyotrophic lateral sclerosis mouse model with hSOD1G93A mutation. Molecular and Cellular Neuroscience, 90, 1-11. https://doi.org/10.1016/j.mcn.2018.05.00
21. Pinilla-González, V., Montecinos-Barrientos, B., Martin-Kommer, C., Chichiarelli, S., Saso, L., & Rodrigo, R. (2024). Exploring antioxidant strategies in the pathogenesis of ALS. Open Life Sciences, 19(1), 20220842. https://doi.org/10.1515/biol-2022-0842
22. Kinger, S., Jagtap, Y. A., Kumar, P., Choudhary, A., Prasad, A., Prajapati, V. K., et al. (2024). Proteostasis in neurodegenerative diseases. Advances in Clinical Chemistry, 121, 270-333. https://doi.org/10.1016/bs.acc.2024.04.002
23. Tosolini, A. P., Sleigh, J. N., Surana, S., Rhymes, E. R., Cahalan, S. D., & Schiavo, G. (2022). BDNF-dependent modulation of axonal transport is selectively impaired in ALS. Acta Neuropathologica Communications, 10(1), 121. https://doi.org/10.1186/s40478-022-01418-4
24. Goutman, S. A., Boss, J., Godwin, C., Mukherjee, B., Feldman, E. L., & Batterman, S. A. (2022). Associations of self-reported occupational exposures and settings to ALS: a case-control study. International Archives of Occupational and Environmental Health, 95(7), 1567-1586. https://doi.org/10.1007/s00420-022-01874-4
25. Chalitsios, C. V., Rudolf, O., Gao, J., Turner, M. R., & Thompson, A. G. (2026). Long-term exposure to ambient air pollution and incident amyotrophic lateral sclerosis: A prospective cohort analysis of the UK Biobank. Neurology, 106(8), e214858. https://doi.org/10.1212/WNL.0000000000214858
26. Malek, A. M., Arena, V. C., Song, R., Whitsel, E. A., Rager, J. R., Stewart, J., et al. (2023). Long-term air pollution and risk of amyotrophic lateral sclerosis mortality in the Women’s Health Initiative cohort. Environmental Research, 216(Pt 1), 114510. https://doi.org/10.1016/j.envres.2022.114510
27. Pedde, M., Adar, S. D., Jang, D. G., Feldman, E. L., & Goutman, S. A. (2026). Air pollution and mortality in a University of Michigan amyotrophic lateral sclerosis cohort: a survival analysis. Environmental Health. https://doi.org/10.1186/s12940-026-01295-7
28. Peters, S., Broberg, K., Gallo, V., Levi, M., Kippler, M., Vineis, P., et al. (2021). Blood Metal Levels and Amyotrophic Lateral Sclerosis Risk: A Prospective Cohort. Annals of Neurology, 89(1), 125-133. https://doi.org/10.1002/ana.25932
29. Jang, D. G., Dou, J. F., Koubek, E. J., Teener, S., Zhou, L., Bakulski, K. M., et al. (2025). Multiple metal exposures associate with higher amyotrophic lateral sclerosis risk and mortality independent of genetic risk and correlate to self-reported exposures: a case-control study. Journal of Neurology, Neurosurgery & Psychiatry, 96(4), 329-339. https://doi.org/10.1136/jnnp-2024-333978
30. Kim, K., Ko, D. S., Kim, J. W., Lee, D., Son, E., Kim, H. W., et al. (2024). Association of smoking with amyotrophic lateral sclerosis: A systematic review, meta-analysis, and dose-response analysis. Tobacco Induced Diseases, 22. https://doi.org/10.18332/tid/175731
31. Clackson, O., Hamid, M. R., Wijesekera, A., Kulick, D., & O’Neil, A. L. (2025). Exposure to the organochlorine pesticide cis-chlordane induces ALS-like mitochondrial perturbations in stem cell-derived motor neurons. PLoS One, 20(10), e0332422. https://doi.org/10.1371/journal.pone.0332422
32. Andrew, A., Zhou, J., Gui, J., Harrison, A., Shi, X., Li, M., et al. (2021). Pesticides applied to crops and amyotrophic lateral sclerosis risk in the U.S. Neurotoxicology, 87, 128-135. https://doi.org/10.1016/j.neuro.2021.09.004
33. Talbott, E. O., Malek, A. M., Arena, V. C., Wu, F., Steffes, K., Sharma, R. K., et al. (2024). Case-control study of environmental toxins and risk of amyotrophic lateral sclerosis involving the national ALS registry. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 25(5-6), 533-542. https://doi.org/10.1080/21678421.2024.2336108
34. Ueda, P., Pasternak, B., Lim, C. E., Neovius, M., Kader, M., Forssblad, M., et al. (2023). Neurodegenerative disease among male elite football (soccer) players in Sweden: a cohort study. Lancet Public Health, 8(4), e256-e265. https://doi.org/10.1016/S2468-2667(23)00027-0
35. Daneshvar, D. H., Mez, J., Alosco, M. L., Baucom, Z. H., Mahar, I., Baugh, C. M., et al. (2021). Incidence of and Mortality From Amyotrophic Lateral Sclerosis in National Football League Athletes. JAMA Network Open, 4(12), e2138801. https://doi.org/10.1001/jamanetworkopen.2021.38801
36. Chiò, A., Benzi, G., Dossena, M., Mutani, R., & Mora, G. (2005). Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain, 128(Pt 3), 472-476. https://doi.org/10.1093/brain/awh373
37. Zhu, Q., Zhou, J., Zhang, Y., Huang, H., Han, J., Cao, B., et al. (2023). Risk factors associated with amyotrophic lateral sclerosis based on the observational study: a systematic review and meta-analysis. Frontiers in Neuroscience, 17, 1196722. https://doi.org/10.3389/fnins.2023.1196722
38. Vaage, A. M., Meyer, H. E., Landgraff, I. K., Myrstad, M., Holmøy, T., & Nakken, O. (2024). Physical Activity, Fitness, and Long-Term Risk of Amyotrophic Lateral Sclerosis: A Prospective Cohort Study. Neurology, 103(2), e209575. https://doi.org/10.1212/WNL.0000000000209575
39. Vasta, R., Ombelet, F., Hobin, F., Manera, U., Al-Chalabi, A., Caravaca Puchades, A., et al. (2025). Real-world prognostic role of riluzole use in ALS: a multi-center study from PRECISION-ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 26(sup1), 50-60. https://doi.org/10.1080/21678421.2025.2472889
40. Berry, J. D., Hagan, M., Zhang, J., Liu, Y., & Ciepielewska, M. (2025). Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative claims analysis. Journal of Comparative Effectiveness Research, 14(2), e240007. https://doi.org/10.57264/cer-2024-0007
41. Paganoni, S., Quintana, M., Sherman, A. V., Vestrucci, M., Wu, Y., Timmons, J., et al. (2023). Analysis of sodium phenylbutyrate and taurursodiol survival effect in ALS using external controls. Annals of Clinical and Translational Neurology, 10(12), 2297-2304. https://doi.org/10.1002/acn3.51915
42. Miller, T. M., Cudkowicz, M. E., Shaw, P. J., Genge, A., Sobue, G., Bucelli, R. C., et al. (2026). Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis. JAMA Neurology, 83(2), 115-125. https://doi.org/10.1001/jamaneurol.2025.4946
43. Oki, R., Izumi, Y., Fujita, K., Miyamoto, R., Nodera, H., Sato, Y., et al. (2022). Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurology, 79(6), 575-583. https://doi.org/10.1001/jamaneurol.2022.0901
44. Frawley, L., Taylor, N. T., Sivills, O., McPhillamy, E., To, T. D., Wu, Y., et al. (2024). Stem Cell Therapy for the Treatment of Amyotrophic Lateral Sclerosis: Comparison of the Efficacy of Mesenchymal Stem Cells, Neural Stem Cells, and Induced Pluripotent Stem Cells. Biomedicines, 13(1), 35. https://doi.org/10.3390/biomedicines13010035
45. Zhang, J., Guo, R., Zhou, Z., Fu, Z., Akogo, H. Y., Li, Y., et al. (2025). Neural Stem/Progenitor Cell Therapy in Patients and Animals with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis. Molecular Neurobiology, 62(5), 6521-6536. https://doi.org/10.1007/s12035-024-04682-8
46. Verdés, S., Navarro, X., & Bosch, A. (2025). Targeting Amyotrophic Lateral Sclerosis with Gene Therapy: From Silencing Genes to Enhancing Neuroprotection. Human Gene Therapy, 36(17-18), 1173-1198. https://doi.org/10.1177/10430342251372898
47. Khan, H., Riaz, H., Ahmed, A., Kiyani, M. M., Jawad, S. M., Ud Din Shah, S. S., et al. (2025). CRISPR/Cas9 a genomic engineering technology for treatment in ALS mouse models. Regenerative Therapy, 30, 575-583. https://doi.org/10.1016/j.reth.2025.07.009
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Natalia Zięba, Olgierd Czapiński, Anna Brodowska, Anna Knapik, Patrycja Białowąs, Mateusz Pysiewicz, Justyna Kuś, Maciej Ciesielski, Ewa Tomicka, Olga Stadnicka , Mateusz Czech
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 32
Number of citations: 0
